NEW YORK, June 21, 2021 /PRNewswire/ -- Chardan, a
global investment bank, today announced that it acted as lead left
bookrunner in the successful closing of the $34.45 million IPO of Femasys, Inc. (NASDAQ:
FEMY) a biomedical company focused on transforming women's
healthcare by developing novel solutions and next-generation
advancements providing significant clinical impact to address
severely underserved areas.
"We are delighted to work with the outstanding team at Femasys
in support of their commitment to women's healthcare," said
Matthew Mrozinski, a partner in the
investment banking group at Chardan. "Chardan's goal as a bank is
to identify and support companies that address areas of significant
unmet need. Femasys' mission of transforming women's healthcare is
a substantial market opportunity."
This transaction further solidifies Chardan's dedication to ESG
and healthcare companies with novel and differentiated platforms.
Since 2020, Chardan has acted as book
runner or lead placement agent in 32 transactions including
for healthcare companies: 4D Pharma plc (PIPE), Forge Biologics
(Private offering) Forte Biosciences (FO), GenSight Biologics
(PIPE), Immunome (IPO), Immunovant (FO), MeiraGTx (FO), NeuBase
Therapeutics (FO), and Renovacor (announced PIPE).
Femasys is a woman-led company founded by Kathy Lee-Sepsick, President, CEO and Founder.
Femasys will use the proceeds of their IPO to fund the completion
of enrollment in the stage 2 clinical trial and commencement of the
stage 3 clinical trial for the FemBloc system and for the
initiation and completion of the pivotal trial for the FemaSeed
system. The proceeds will also be used to fund product development
and research and development activities, to hire additional
personnel, and for working capital and general corporate
purposes.
About Chardan
Chardan is an independent global investment bank specializing in
healthcare, SPACs and emerging growth companies. Our range of
services include capital raising, merger and acquisition advisory,
strategic advisory, equity research, corporate access, and
institutional trading. Headquartered in New York City, Chardan
is a registered broker-dealer with the U.S. Securities and Exchange
Commission and is a member of the following: FINRA, SIPC, NASDAQ
and the NYSE Arca, Inc.
Media Inquiries:
Emily Levine, Chardan
elevine@chardan.com
(646) 465-9018
Margaret Gaenzle, Prosek
Partners
mgaenzle@prosek.com
(804) 714-8848
View original
content:http://www.prnewswire.com/news-releases/chardan-acts-as-lead-left-bookrunner-in-femasys-34-45-million-ipo-301316312.html
SOURCE Chardan